These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of Src tyrosine kinase inhibition on the drug-resistance as well as MDR1 and LRP expression of the human cis-platinum-resistant lung cancer cell line A549/DDP].
    Author: Lv J, Tian Y.
    Journal: Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):501-6. PubMed ID: 22989452.
    Abstract:
    BACKGROUND: The aim of this study is to investigate the effect of Src tyrosine kinase inhibition on the drug-resistance as well as the expression of multidrug resistance 1 (MDR1) and lung resistance-related protein (LRP) of the human cis-platinum-resistant lung cancer cell line A549/DDP. METHODS: 4-Anilinoquirazoline was used to inhibit Src tyrosine kinase activity in A549/DDP. Western blot analysis was used to detect the Src tyrosine kinase activity. CellTiter-Glo assay was used to detect the drug sensitivity of tumor cells. Flow cytometry was used to detect the intracellular Rh-123 content. Western blot and real-time PCR assay were used to detect the expression of tumor MDR1 and LRP. RESULTS: 4-Anilinoquirazoline can down-regulate the cellular Src tyrosine kinase activity in A549/DDP. After treatment with 2.5 μM and 10 μM of 4-anilinoquirazoline, the cells became more sensitive to the drug and the reversal folds (RFs) of tumor cell sensitivity to the drug were 1.59- and 2.10-fold, respectively. The intracellular content of Rh-123 improved by 1.21- and 1.59-fold, respectively. The mRNA levels of MDR1 were 53.8% and 27.5% of the control, respectively. The mRNA level of LRP was 59.3% and 21.4% of the control, respectively. The expression of MDR1 and LRP protein significantly decreased. CONCLUSIONS: The inhibition of Src tyrosine kinase activity in A549/DDP cells can reverse multi-drug resistance and increase the sensitivity of the cells to the drug. The mechanism may be related to the down-regulation of cellular MDR1 and LRP. 背景与目的: 本研究旨在探讨抑制Src酪氨酸激酶活性对人肺癌A549/DDP细胞耐药性及多药耐药蛋白（muti-drug resistance 1, MDR1）和肺耐药相关蛋白（lung resistance-related protein, LRP）表达的影响。 方法: 以Src酪氨酸激酶抑制剂作用于A549/DDP细胞，应用Western blot法检测肿瘤细胞Src酪氨酸激活性的变化，CellTiter-Glo发光法检测肿瘤细胞药物敏感性的变化，流式细胞仪检测肿瘤细胞Rh-123含量变化，Western blot法和RT-PCR检测肿瘤细胞MDR1和LRP表达变化。 结果: Src酪氨酸激酶抑制剂可下调A549/DDP细胞中Src酪氨酸激活性，2.5 μM和10 μM Src酪氨酸激酶抑制剂作用肿瘤细胞后，肿瘤细胞药物敏感性提高，逆转倍数（reversal fold, RF）分别为1.59倍和2.10倍，肿瘤细胞中Rh-123含量分别提高了1.21倍和1.59倍，MDR1 mRNA表达分别是对照组的53.8%和27.5%，LRP mRNA表达分别是对照组的59.3%和21.4%，MDR1和LRP蛋白表达水平明显下降。 结论: 抑制A549/DDP细胞中Src酪氨酸激酶活性可逆转肿瘤细胞多药耐药性，提高肿瘤细胞药物敏感性，其机制可能与降低细胞MDR1和LRP表达有关。
    [Abstract] [Full Text] [Related] [New Search]